Press release
Psoriasis Patient Pool Analysis Market Forecast to Reach USD 32.5 Billion by 2034
Psoriasis Patient Pool Analysis Market
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71525
The psoriasis patient pool is steadily expanding due to rising diagnosis rates, better awareness campaigns, and improved access to dermatology care. Biologic therapies and small-molecule drugs are transforming disease management, while early diagnosis and personalized treatment are reshaping long-term outcomes. Between 2024 and 2034, the psoriasis patient pool analysis market is projected to grow significantly, creating new opportunities for pharmaceutical companies and healthcare providers.
Market Overview
The global psoriasis patient pool analysis market size in 2024 is estimated at USD 17. billion and is forecast to reach USD 32.5 billion by 2034, growing at a CAGR of 6.5% over the forecast period.
Key highlights:
• Rising prevalence of psoriasis worldwide, particularly in Europe and North America.
• Expanding availability of biologics and novel oral therapies for moderate-to-severe cases.
• Increasing patient awareness and early dermatology consultations.
• Growing investments in clinical trials targeting immune pathways (IL-17, IL-23, TNF-α).
• Asia-Pacific emerging as a high-growth region due to increasing diagnosis rates.
Market Segmentation
By Product
• Topical Treatments (Corticosteroids, Vitamin D Analogues, Coal Tar, Others)
• Phototherapy Devices
• Oral Systemic Therapies (Methotrexate, Cyclosporine, Apremilast)
• Biologics & Targeted Therapies (TNF Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors, Others)
• Others
By Technology
• Conventional Therapies
• Biologic Therapies
• Digital Health & Teledermatology Tools
By Platform
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End Use
• Hospitals & Dermatology Clinics
• Ambulatory Care Centers
• Homecare Settings
By Application
• Plaque Psoriasis
• Guttate Psoriasis
• Inverse Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis
Summary of Segmentation
Biologics dominate the moderate-to-severe psoriasis treatment landscape, while topical agents remain widely used in mild cases. Teledermatology and digital monitoring platforms are enhancing patient engagement and adherence, particularly in homecare and remote regions.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71525/psoriasis-patient-pool-analysis-market
Regional Analysis
North America
• Largest share in 2024 due to advanced dermatology infrastructure, high biologic adoption, and strong presence of leading pharmaceutical companies.
• The U.S. leads clinical research into next-generation biologics and small molecules.
Europe
• Second-largest market, with high prevalence in Scandinavia, Germany, and the UK.
• Strong healthcare access and patient advocacy initiatives support treatment adoption.
Asia-Pacific
• Fastest-growing region through 2034.
• Rising prevalence in China, India, and Japan, coupled with growing awareness campaigns.
• Expanding availability of cost-effective biosimilars is improving access to biologics.
Middle East & Africa
• Gradual adoption due to limited dermatology care facilities, but growth is expected as healthcare access expands.
Latin America
• Brazil and Mexico lead, supported by rising dermatology consultations and broader healthcare coverage.
Regional Summary
While North America and Europe dominate, Asia-Pacific offers the strongest growth potential, supported by an expanding patient base and improving access to advanced therapies.
Market Dynamics
Growth Drivers
• Increasing global prevalence of psoriasis.
• Strong adoption of biologics and targeted therapies.
• Rising patient awareness through advocacy campaigns and digital platforms.
• Expanding role of biosimilars in improving affordability.
Key Challenges
• High treatment costs of biologics in low- and middle-income countries.
• Adherence issues with long-term therapies.
• Diagnostic challenges in differentiating psoriasis from other dermatological conditions.
• Unequal access to dermatology specialists worldwide.
Latest Trends
• IL-17 and IL-23 inhibitors emerging as highly effective biologics.
• Expansion of teledermatology platforms for patient follow-up and disease management.
• Increasing research into oral small-molecule therapies (e.g., TYK2 inhibitors).
• Growing emphasis on personalized medicine and biomarker-driven treatment.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71525
Competitive Landscape
Major Players
• Novartis AG (Cosentyx, IL-17 inhibitor)
• AbbVie Inc. (Humira, Skyrizi)
• Johnson & Johnson (Stelara, Tremfya)
• Amgen Inc. (Enbrel, Otezla)
• Eli Lilly and Company (Taltz)
• Bristol-Myers Squibb (Sotyktu - TYK2 inhibitor)
• UCB Pharma (Bimzelx)
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Pfizer Inc.
• Biogen Inc.
Competition Summary
The psoriasis patient pool market is highly competitive, with AbbVie, Novartis, and Johnson & Johnson leading due to their strong biologic portfolios. Amgen and Eli Lilly are also key players with successful targeted therapies. Meanwhile, biosimilars and new oral small molecules are intensifying competition, particularly in emerging markets.
Conclusion
The psoriasis patient pool analysis market is set for steady expansion through 2034, fueled by rising prevalence, wider access to biologics, and advances in targeted therapies. As patient awareness improves and healthcare systems embrace teledermatology, psoriasis management is shifting toward earlier intervention and personalized care.
Despite cost barriers and uneven access, opportunities abound in biosimilars, digital platforms, and emerging economies. For pharmaceutical companies and healthcare providers, psoriasis represents a rapidly evolving market with high potential for innovation and growth.
Key Takeaways:
• Rising prevalence of psoriasis globally is expanding the patient pool.
• Biologics dominate today, but biosimilars and small molecules will shape future growth.
• North America and Europe lead, while Asia-Pacific is the fastest-growing region.
• Personalized medicine and digital platforms are redefining patient care.
This report is also available in the following languages : Japanese (乾癬患者プール分析市場), Korean (건선 환자 풀 분석 시장), Chinese (牛皮癣患者群体分析市场), French (Analyse du marché des patients atteints de psoriasis), German (Marktanalyse für Psoriasis-Patientenpools), and Italian (Analisi del mercato dei pazienti affetti da psoriasi), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71525/psoriasis-patient-pool-analysis-market#request-a-sample
Our More Reports:
Atypical Teratoid Rhabdoid Tumors Market
https://exactitudeconsultancy.com/reports/71926/atypical-teratoid-rhabdoid-tumors-market
Chronic Brain Damage Market
https://exactitudeconsultancy.com/reports/71927/chronic-brain-damage-market
Chronic Progressive Multiple Sclerosis Market
https://exactitudeconsultancy.com/reports/71928/chronic-progressive-multiple-sclerosis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Patient Pool Analysis Market Forecast to Reach USD 32.5 Billion by 2034 here
News-ID: 4170272 • Views: …
More Releases from Exactitude Consultancy
Viral Vector Manufacturing Market to Surge to USD 43.04 Billion by 2034, Growing …
Introduction
The healthcare industry is entering a transformative era where precision therapies are reshaping how we treat diseases. Among the most groundbreaking innovations, viral vectors have emerged as critical enablers of gene and cell therapies. These engineered viruses act as vehicles to deliver therapeutic genetic material directly into patients' cells, making them indispensable for modern medicine. From treating rare genetic disorders to powering revolutionary CAR-T cell therapies in oncology, viral vectors…
Veterinary Vaccines Market to Reach USD 20.65 Billion by 2034, Growing at 6.4% C …
Introduction
Animal health is a cornerstone of global food security, sustainable agriculture, and public health. With rising concerns over zoonotic diseases, antimicrobial resistance, and livestock productivity, the role of veterinary vaccines has never been more critical. These vaccines not only protect animal populations from infectious diseases but also indirectly safeguard humans by preventing disease transmission from animals.
In 2024, the global Veterinary Vaccines Market is valued at USD 11.25 billion and is…
Intravenous Immunoglobulin (IVIG) Market to Reach USD 27.1 Billion by 2034, Grow …
Introduction
In recent years, the healthcare industry has seen significant progress in therapies targeting immune system disorders and rare diseases. At the forefront of these therapies is Intravenous Immunoglobulin (IVIG) - a plasma-derived product containing antibodies that play a crucial role in strengthening or modulating immune response. IVIG is widely used in treating primary and secondary immunodeficiency disorders, autoimmune diseases, neurological disorders, and hematological conditions.
With the rising prevalence of chronic illnesses,…
Lipid Nanoparticle Manufacturing Market to Reach USD 2.48 Billion by 2034, Growi …
Introduction
The pharmaceutical and biotechnology industries are undergoing a paradigm shift driven by the success of mRNA vaccines and the growing promise of gene therapies. At the heart of these breakthroughs are lipid nanoparticles (LNPs) - tiny, lipid-based carriers that safely deliver nucleic acids like mRNA, siRNA, and DNA into target cells. LNPs are now recognized as the gold standard for nucleic acid delivery, fueling advancements in infectious disease prevention, oncology,…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
